Background Microenvironments control cancer growth and progression. We explored the prognostic impact of stromal reaction and cancer stromal cells on relapse risk and survival after curative gastrectomy in gastric cancer patients. Methods Tissue samples were obtained from 107 patients with gastric adenocarcinoma who underwent curative (R0) gastrectomy. Primary stromal cells isolated from gastric cancer tissue (GCSC) and normal gastric tissue (Gastric stromal cell: GSC) in each patient were cultured and subjected to comprehensive proteome (LC-MS/MS) and realtime RT-PCR analysis. Expression of Ephrin A2 receptors (EphA2) in cancers and GCSC was evaluated immunohistochemically. Intermingling of EphA2-positive cancer cells and GCSC (IC/A2?) and overexpression of EphA2 in cancer cells (Ca/A2?) in invasive parts of tumors were assessed, as were relationships of IC/A2?, Ca/A2?, and clinicopathological factors with relapse-free survival and overall survival. Results Proteome analysis showed that EphA2 expression was significantly higher in GCSC than GSC. Real-time RT-PCR analysis showed that levels of EphA1/A2/A3/A5 and EphB2/B4 were C2.0-fold higher in GCSC than GSC. Ca/ A2 and IC/A2 were positive in 65 (60.7 %) and 26 (24.3 %) patients, respectively. Relapse was significantly more frequent in IC/A2-positive than in IC/A2-negative (HR, 2.12; 95 % CI, 1.16-5.41; p = 0.0207) patients. Among the 54 patients who received S-1 adjuvant chemotherapy, relapse-free survival (RFS) was significantly shorter in those who were IC/A2-positive than in those who were IC/A2-negative and Ca/A2-negative (HR, 2.83; 95 % CI, 1.12-12.12; p = 0.0339). Multivariable analysis indicated that pathological stage (p = 0.010) and IC/A2? (p = 0.008) were independent risk factors for recurrence. Conclusion IC/A2? was predictive of relapse after curative (R0) gastrectomy.
Introduction
Gastric cancer is the second leading cause of cancer deaths in both sexes worldwide (736,000 deaths, 9.7 % of the total). Sufficient surgical resection plus regional lymph node dissection in experienced centers have been shown to significantly improve overall survival (OS). Complete resection of the primary tumor and any local spread, including lymph node metastasis, is essential for cure. Other therapeutic approaches, such as chemotherapy, hormonal therapy, and radiotherapy, are insufficiently effective in preventing tumor recurrence. Combination chemotherapy regimens consisting of two or three cytotoxic agents results in an OS of 10-13 months in patients with unresectable or metastatic gastric cancer [1, 2] . Some patients who undergo R0 (curative) resection followed by postoperative therapy experience tumor relapse. At present, only tumor node metastasis (TNM) classification is predictive of relapse after adjuvant treatment.
Erythropoietin-producing hepatocellular (Eph) receptors are novel targets for anti-cancer agents, because EphA2 is frequently overexpressed in a variety of human epithelial cancer [3] [4] [5] . This overexpression is often associated with an aggressive tumor phenotype [6, 7] . Eph receptors are the largest known family of receptor tyrosine kinases (RTKs), and are activated by interacting with cell-surface ligands, termed ephrins. Eph receptors are classified into A-type (EphA1-8 and EphA10) and B-type (EphB1-4 and EphB6) based on their interactions with ephrin ligands, which are also classified as A-type and B-type. Eph receptors and ephrin ligands control cell morphology, adhesion, migration, and invasion by modifying the organization of the actin cytoskeleton and influencing the activities of integrins and intercellular adhesion molecules in bidirectional signaling pathways [8] .
Cancer tissue is composed of cancer cells and stromal cells such as fibroblasts, monocyte/macrophages, endothelial cells, and immune cells (lymphocytes and neutrophils). Cancer progression is not solely determined by the cancer cells themselves, but also by the surrounding stromal cells [9-15.] We found that EphA2 was locally overexpressed in both cancer cells and gastric cancer tissue (GCSC) in invasive parts of tumors, but the function of EphA2 in these cells is still unclear. We therefore assessed the prognostic impact of stromal reaction and EphA2 expression in cancer cells and GCSC. To our knowledge, this study is the first to assess whether EphA2 overexpression in GCSC is predictive of the risk of relapse after curative gastrectomy in patients with gastric cancer.
Methods

Patients
We retrospectively analyzed findings in 107 patients who underwent curative (R0) resection of primary gastric adenocarcinoma at Hyogo College of Medicine, Japan, between 2008 and 2010. Patients were included if they had histologically proven T2-T4b gastric cancer; had undergone R0 resection with D2 or more extensive lymph-node dissection; had no distant metastases or tumor cells on peritoneal lavage cytology; and did not receive treatment prior to surgery. Following surgery, 79 patients (73.8 %) were eligible for adjuvant chemotherapy, and 54 patients (50.5 %) received adjuvant chemotherapy without severe adverse effects, consisting of 80 mg/m 2 S-1 (tegafur-gimeracil-oteracil potassium) administered orally on days 1-28 every 6 weeks, for eight cycles. The median followup period was 1,279 days (range 163-2,106 days). During the study, 13 patients died from gastric cancer relapse and five from other causes. Tumor recurrence was observed in 39 patients, including 15 with blood-borne, 14 with peritoneal, six with lymph node, and four with other types of recurrence. Patients were followed up monthly for the first year and every 3 months thereafter. Relapse was determined by imaging modalities, including ultrasonography, computed tomography (CT, performed every 3-6 months), gastrointestinal radiography, endoscopy, positive emission tomography/CT scan, blood tests (every 1-3 months) and ascites cytology.
Study design and treatment
The study protocol was approved by the Institutional Medical Ethics Committees of Hyogo College of Medicine. Written informed consent was obtained from all patients. The primary endpoint was relapse-free survival (RFS) and overall survival (OS). Clinicopathological data on all patients were collected prospectively. Tumors were classified according to the TNM system of the International Union Against Cancer (UICC), 7th edition, and the Japanese Classification of Gastric Carcinoma, 14th edition [16] .
Pathological classification and IC
Formaldehyde (10 %)-fixed and paraffin-embedded specimens of surgically resected samples were used for hematoxylin-eosin (HE) staining and immunohistochemistry. All samples were histologically analyzed by a pathologist, to determine pathological diagnosis and intermingling of scattered cancer cells and GCSC (IC), with or without EphA2 expression. ICs were defined as (1) scattered cancer cells intermingled with GCSC in invasive parts of tumors; and (2) staining for EphA2 in cancer cells or GCSC that was equal to or stronger than in the soma of Auerbach's plexus, in which EphA2 is normally expressed. ICs positive and negative for EphA2 expression in invasive parts of tumors were designated IC/A2? and IC/A2-, respectively. IC/A2 consists of double-positive cancer cells and GCSC in invasive parts of tumor. EphA2 staining of [50 % of cancer cells throughout the tumor was designated as Ca/ A2?. We analyzed the cancer-stromal mixture in 107 cases, but we couldn't find any case of EphrinA2-positive only in GCSC and not in cancer cells. Although gastric cancer has been defined as intestinal and diffuse types, most of these tumors consisted of heterogeneous tissue. If the pathological type of the major and invasive parts of the tumor differed, the tumor was defined as transitional type.
Primary cultured stromal cells
Following resection, tissue samples were prepared from cancerous lesions (GCSC) and non-cancerous areas at least 50 mm removed from the tumor (GSC). The specimens were trimmed of fat and necrotic tissues, minced, and transferred to 12-well microplates. Cells were cultured in Dulbecco's modified Eagle's medium (GIBCO, Grand Island, NY) supplemented with 10 % fetal calf serum. Isolated fibroblasts were transferred to other dishes and used for experiments within eight passages.
Proteome analysis of stromal cells
Liquid chromatography-tandem mass spectrometry (LC-MS/MS analysis) Sample preparation for LC-MS/MS analysis Stromal cells (2 9 10e6 cells) were lysed in 100 mM Tris-HCl, pH 8.8, 7 M urea, 2 % SDS. Cell lysates were sonicated using Bioraptor and subjected to protein assay (BCA method) and clarified by centrifugation for 20 min at 13,500 rpm. Proteins (200 mg) were then precipitated using methanolchloroform, resuspended in a buffer containing 7 M guanidium hydroxide in 0.5 M triethylammonium hydrogen carbonate pH 8.5, and incubated for 15 min at 85°C. The sample was diluted with fourfold volumes of water and digested with Lys-C at 37°C for 4 h; this was followed by twofold dilution and trypsin digestion at 37°C overnight (enzyme-to-protein ratio of 1:100 [w/w]). After reduction with 0.625 mM TCEP and alkylation with 3.125 mM iodoacetamide (IAA), digests were stored at -80°C until analysis.
LC-MS/MS analysis All samples were analyzed by Q Exactive (Thermo Fisher Scientific), equipped with an AdvanceLC HPLC pump and HTC-PAL autosampler (CTC Analytics AG, Zwingen, Switzerland). L-column C18 materials (3 lm, CERI Japan) were packed into selfpulled fused silica capillaries (100 lm inner diameters, 20 cm length) by using a high pressure chamber equipped with an HPLC pump at constant pressure of 230 bar. All samples were dissolved in 0.1 % TFA, 2 % acetnitrile, and injected to pre-column (L-column micro: 0.3 mm inner diameter, 5 mm length, CERI Japan), washed with the same buffer, and eluted with a linear gradient of 5-35 % B for 90 min, 35-95 % B for 1 min, and 95-95 % B for 10 min (A: 0.1 % formic acid, 2 % acetonitrile, B: 0.1 % formic acid, 90 % acetnitrile) at a flow rate of 200 nl/min. The Q Exactive was operated in the data-dependent mode with survey scans acquired at a resolution of 70,000 at m/ z 200. The top ten most abundant ions were selected with an isolation window of 1.5 Thomsons and fragmented by higher energy collisional dissociation with normalized collision energies of 35. The ion target values were set to 1e6 for survey scan and 5e5 for MS/MS scan, respectively. The maximum ion injection times for both survey scan and MS/MS scan were 60 ms. Dynamic exclusion times was 60 s. Fibroblasts (2 9 10 6 cells) were lysed and sonicated. Following the determination of protein concentrations using the bicinchoninic acid method, 200 mg proteins were denatured and digested. All samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS), using Q Exactive (Thermo Fisher Scientific), equipped with an AdvanceLC HPLC pump and HTC-PAL autosampler (CTC Analytics AG, Zwingen, Switzerland). L-Column C18 materials (3 lm, CERI Japan) were packed into self-filling fused silica capillaries using a high pressure chamber equipped with an HPLC pump. The Q Exactive was operated in the data-dependent mode with survey scans. The ten most abundant ions were selected with an isolation window and fragmented by higher energy collisional dissociation with normalized collision energies. The ion target values were set to survey scan and MS/MS scan, respectively.
Real-time RT-PCR and RNA microarray of stromal cells
Total RNA was extracted from three sets of CAFs and NGFs using Trizol reagent (Gibco BRL, Rockville, MD). Real-time RT-PCR analysis were performed according manufacture's protocol (Power SYBR Ò Green PCR, applied biosystems, Warrington, UK) using Ephrin primers (Supplementary Table 1 ) by ABI SDS-7900HT (ABI). For RNA Microarray analysis, synthesis of cRNA, hybridization, scanning and data analysis were performed by Hokkaido System Science Co., Ltd. (Sapporo, Japan). Briefly, cyanine-3 (Cy3) labeled cRNA was prepared from total RNA (0.05 lg) using the Low Input Quick Amp Labeling Kit (Agilent) according to the manufacturer's instructions. These Cy3-labeled cRNAs (0.60 lg) were fragmented and hybridized to Agilent SurePrint G3 Human Gene Expression Microarrays (8 9 60 K ver.2.0). All fibroblast samples were assayed in triplicate. Those samples on the microarrays that showed significantly different expression when hybridized with labeled cRNA from GCSC and GSC were quantified using the peak area of precursor ion extracted at 5 ppm tolerance.
Antibodies and immunohistochemistry
Formalin-fixed, paraffin-embedded tissue samples were cut 3 lm thick using the Ventana BenchMark XT system (Ventana Medical Systems, Tucson, AZ, USA). After antigen retrieval and quenching by immersion in 3 % hydrogen peroxide, the tissue sections were incubated with primary antibodies (Abs) to EphA2 (Santa Cruz Biotechnology; Santa Cruz, CA, USA), pan-keratin (AE1/AE3; clone PCK26), a-smooth muscle actin (a-SMA; clone 1A4) and vimentin (clone V9) (all from Roche; Basel, EphA2 was upregulated 2.221-fold (experiment #1) and 4.967-fold (experiment #2). EphA5 was upregulated 10.610-fold in experiment #2, and keratins 8 and 15 and lysine-6-oxidase were upregulated in experiment #1. Taken together, these findings suggest that re-organization of the cytoskeleton and extracellular matrix, including collagens, was activated in GCSC Switzerland), and D2-40 (podoplanin, 760-4395, CELL MARQUE; Rocklin, CA, USA). Binding was detected using the iVIEW DAB Universal Kit, according to the manufacturer's instructions, and all sections were counterstained with hematoxylin.
Statistical analysis
The v 2 test was used to analyze possible associations of Eph receptor expression with clinicopathological variables. RFS was calculated using the Kaplan-Meier method and compared using the log-rank test. Multivariate proportional Cox models were used to assess the prognostic significance of factors on RFS. P values less than 0.05 were considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics 19 software (IBM Inc., Armonk, NY, USA).
Results
Proteome analysis and expression analysis of stromal cells
Proteome analyses were performed using LC-MS/MS methods. Upregulated peptides (GCSC/GSC ratios [ 2.0, p \ 0.05) are shown in Table 1 . Interestingly, only 16 and six peptides were upregulated in GCSC in experiments 1 and 2, respectively. EphA2 was upregulated in these two experiments 2.221-fold and 4.967-fold, respectively. EphA5 was upregulated 10.610-fold in experiment 2, whereas keratins 8 and 15 and lysine-6-oxidase were upregulated in experiment 1.
Real-time RT-PCR analysis showed that EphA1, EphA2, EphA3, EphA5, EphB2, and EphB4 were upregulated 3.50-, 4.76-, 2.36-, 3.57-, 2.93-, and 2.86-fold, respectively, in GCSC relative to GSC in each patient (Fig. 1) . Quantitative RNA microarray analysis of the levels of expression of all isoforms of the ephrin family showed that EphA2 and EphB2 were upregulated 2.28-fold and 2.22-fold, respectively, in GCSC relative to GSC in each patient. The GCSC/GSC expression ratios of other ephrin receptor isoforms ranged from 0.5 to 2.0 (n = 3). All sets of fibroblasts were obtained from diffuse-type gastric cancers (Supplementary Figure 1) .
Immunohistochemistry
Scattered cancer cells and stromal cells, mostly consisting of fibroblasts, formed intermingled complexes in the invasive part of transitional-type tumors (Fig. 2a) and in all parts of diffuse-type tumors (Fig. 2c) . Expression of EphA2 was observed in both cancer cells and GCSC (brown, Fig. 2b, d ). IC/A2? in intestinal-type, transitional type tumors were mostly located at the extremities of the invasive parts. Cancer cells and GCSC expressed EphA2 (Fig. 3a, b) . GCSC in ICs appeared as large or small in shape. EphA2 was normally expressed in the soma of Auerbach's plexus (Fig. 3h, black arrows) . Keratin expression was observed in cancer cells, whereas vimentin expression was observed in GCSC, endothelial cells, and hematopoietic cells (Fig. 3c, d ). Although cultured activated fibroblasts were believed to overexpress a-SMA, we found that large GCSC expressed a-SMA (Fig. 3e , asterisks), whereas most small-shaped GCSC in ICs did not (Fig. 3e) . Large populations of EphrinA2-positive GCSC in IC were vimentin-positive (Fig. 3d) , and keratin-, a-SMA-, CD31-, D2-40-negative (Fig. 3c, e, f, g ). We examine double immunofluorescent staining with a-SMA (green) and EphA2 (red) in Fig. 4 . In the left panel, all GCSC looks EphrinA2-positive and one cell strongly expressed a-SMA (white arrow head). In the right panel, all GCSC were EphA2 negative and some population of GCSC was a-SMA-positive (green, white arrow head). Primary cultured GCSC expressed different levels of a-SMA, and some populations strongly expressed a-SMA. These data suggest that the status of GCSC in IC/A2? might be different from that in cultured and activated myofibroblasts.
Prognostic significance of Ca/A2 and IC/A2 IC/A2± and Ca/A2? were found in 26 (24.3 %) and 65 (60.7 %) of the 107 patients, respectively (Supplementary Fig. 1 Real-time RT-PCR analysis of Ephrin receptors of GCSC and GSC. Real-time RT-PCR analysis showed that EphA1, EphA2, EphA3, EphA5, EphB2, and EphB4 were upregulated 3.50-, 4.76-, 2.36-, 3.57-, 2.93-, and 2.86-fold, respectively, in GCSC relative to GSC in each patient. But there was no significance. All sets of stromal cells were obtained from diffuse-type gastric cancers (n = 6) Ephrin A2 in cancer stromal reaction 489 (Fig. 5b) . Overall survival was similar in IC/A2-and Ca/ A2 positive or negative patients (Fig. 6a, b ). Fig. 5c ). Almost half of the patients classified as IC/A2? experienced recurrence within 1 year after R0 resection, even during the course of adjuvant chemotherapy. Interestingly, overall survival showed minor significant difference in three groups and median survival was 633 days in IC/A2? and 1,398 days in IC/A2-with adjuvant chemotherapy (Fig. 6c) . We suppose that the number of patients was too small to show a statistical difference in this study. Even for a high-risk patient, second or third line chemotherapy was effective in IC/A2? patients.
Prognostic factors including IC/A2
Univariate analysis showed that IC/A2? (p = 0.012), T3-T4 (p = 0.048), and pathological stage (p = 0.003) were significant prognostic factors. In multivariate analysis, IC/ A2? (HR, 2.550; 95 % CI, 1.278-5.090; p = 0.008) and pathological stage (HR, 1.390; 95 % CI, 1.080-1.788; p = 0.010) remained independently prognostic (Supplementary Table 3 ). Correlations between the expression of EphA2 and clinicopathological variables are shown in Supplementary Table 2 . Overexpression of EphA2 in IC was independent of other factors.
Discussion
EphA2 is highly expressed in a variety of cancers, including breast, lung, prostate, urinary bladder, ovarian, esophageal, pancreatic, and colorectal cancers [17] [18] [19] [20] [21] [22] [23] [24] . Overexpression of EphA2 is associated with tumor progression or poor patient survival. Recently, overexpression of EphA2 or A4 was also reported to be associated with poor prognosis in patients with gastric cancer [25] . We observed expression of EphA2 in cancer cells from 65 of 107 (60.7 %) patients with gastric cancer, suggesting that EphA2 may be a good molecular target in gastric cancer, [26, 27] , siRNA/oligonucleotides as inhibitors of Eph expression [28, 29] , peptides/mAb that inhibit Eph-ephrin interactions [30, 31] , cytotoxic mAbs and mAb conjugates [32, 33] , and nanoparticles/mAb as imaging agents [34] [35] [36] . Most of these molecules were found to target cancer cells but not stromal cells, and their effects on tumor progression involving cancer stromal cell interactions were unclear. These interactions through the Eph-ephrin axis may be flexible and adaptable for survival in various microenvironments. EphA2 targeting should regulate deleterious cancer stromal cell interactions and be cytotoxic to cancer cells.
In conclusion, IC/EphA2 expression in invasive parts of tumors was useful in determining a high risk of relapse after curative (R0) surgery for gastric cancer. Further examination of the EphA2-ephrin signaling pathway in cancer stromal cells is essential in the development of agents that target Eph and ephrin. survival in IC/A2? (633 days) was shorter than in IC/A2-(1,398 days), and not significant. d Ca/A2 wasn't a prognostic factor in patients who received adjuvant chemotherapy (p = 0.8121). When cancer was relapsed, most patients received additional chemotherapy, and these data had also proved effectiveness of second or third line chemotherapy in relapse cases. IC/A2? in gastric cancer exactly indicated a risk of relapse, not the biological malignancy of cancer Ephrin A2 in cancer stromal reaction 493
